Five Indiana Life Science Startups Selected for IU Health Incubator at IU LAB Pre-Accelerator powered by gener8tor

The seven-week, non-dilutive gBETA program prepares early-stage founders across biosciences, human health, and biotechnology to gain customer traction and connect with investors.

Indianapolis, IN. - Three Indiana University-affiliated companies (Resolet, NeuroCoolX, Vicentrix) and two other Indiana-based startups have been selected to participate in the Summer 2026 cohort of the IU Health Incubator at IU LAB Pre-Accelerator powered by gener8tor. Based in Indianapolis at 16 Tech Innovation District, the national accelerator program supports early-stage founders commercializing breakthrough technologies at the intersection of biosciences, human health, and biotechnology.The five startups-Resolet, NeuroCoolX, Vicentrix, ResperCare, and VitaWave-will join the third cohort, supported by a partnership between Indiana University Launch Accelerator for Biosciences (IU LAB), Indiana University Health, and global venture capital firm gener8tor.

A program of gener8tor's gBETA accelerator, the IU Health Incubator at IU LAB Pre-Accelerator is a non-equity, non-dilutive, free-to-founders program designed to help early-stage companies meet mentors, gain customer traction and pursue investment opportunities. Startup founders receive intensive concierge coaching over a seven-week span, and access to gener8tor's national network of mentors, customers, corporate partners and investors.

"Our goal is to build the pipeline of future life science entrepreneurs while creating a lasting network of resources that continues to support founders well beyond the program," said Camilo Lozano, Director at gener8tor. "The caliber of applicants for our third cohort demonstrates the growing momentum of Indiana's life science ecosystem and validates the impact this partnership is having."

The five selected companies were chosen out of more than 40 applicants due to their growth potential and investor readiness (see below for additional details on each company).

"Eighteen months into this program, we're seeing exactly the kind of growth we hoped to create with more founders engaging in IU's entrepreneurship ecosystem, more IU-affiliated companies entering the pipeline, and increasing demand for programs that help promising ideas become investable companies," said David Rosenberg, President & CEO of IU LAB. "With three IU-affiliated startups selected for this cohort and more than 40 applicants overall, the momentum is clear. Indiana continues to strengthen its position as a premier destination for life sciences innovation, and IU is committed to ensuring our researchers and entrepreneurs have the resources, networks and pathways they need to build and grow their companies here."

At the end of the program, the startup founders will pitch their companies to investors, community partners and the public at a showcase event at VisionLoft Mass Ave on 235 N. Delaware St, Aug 27th, 4:00pm EST,RSVP link.

Startup companies and founders interested in learning more about gBETA's programming and resources or applying to a future program can visit the gener8torIU LAB Pre-Accelerator website, or reach out to Camilo Lozano at [email protected]. Those interested in mentoring these companies or getting involved in other ways are also encouraged to connect.

###

IU Health Incubator at IU LAB Pre-Accelerator Summer 2026 Cohort

Resolet Inc. is developing a compact, automated therapeutic drug monitoring (TDM) platform that measures drug concentrations from a small blood sample at or near the point of care. By combining low-field magnetic resonance relaxometry, drug-specific magnetic nanoparticle assays and software-guided analysis, Resolet is designed to provide quantitative results during the same care encounter so clinicians can individualize dosing of narrow-therapeutic-index medicines. The initial clinical application is tacrolimus monitoring for transplant patients in emergency and acute-care settings. Resolet has built a working benchtop prototype and received a $305,000 National Science Foundation SBIR Phase I award to advance the core sensing platform toward a clinically deployable system.

Co-Founder: Behzad Sharif, PhD | [email protected]

Co-Founder: Daniel Meier, PhD | [email protected]